Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarucizumab for Dabigatran Reversal in Pediatric Patients
NCT02815670Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2016
- Primary completion
- Oct 2019
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of idarucizumab in hemorrhage, sponsored by Boehringer Ingelheim. Primary endpoint: Number of Participants With Drug-related Adverse Events (AEs) up to 25 days. Started Sep 2016; status: completed.
02
Drugs
idarucizumab
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT02815670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02815670.